RDPAC Calls For Chinese Post-marketing Surveillance For Biosimilars – Peking University Symposium
This article was originally published in PharmAsia News
Executive Summary
China has yet to issue a clear regulatory pathway for biosimilars approvals. The existing, lower standard pathway has the branded industry calling for vigorous post-marketing measures to ensure safety.